Merck Receives European Medicines Agency Acceptance for Review of Marketing Authorization Application for Cladribine Tablets - Seite 2

00436826?term=cladribine&cond=%22Multiple+Sclerosis%22&rank=2
Accessed May 5, 2016.
5. Efficacy of Cladribine Tablets as Add-On to IFN-beta Therapy in
Patients with Active Relapsing MS: Final Results from the Phase II
ONWARD Study. American Academy of Neurology 2016 Meeting
Abstracts.
http://www.abstractsonline.com/pp8/#!/4046/presentation/9728
Accessed May 10, 2016.
6. Current and Emerging Therapies for the Treatment of Multiple
Sclerosis: Focus on Cladribine. Journal of Central Nervous System
Disease. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619698/
Accessed June 14, 2016.

About Cladribine Tablets

Cladribine Tablets is an oral small molecule prodrug that
selectively and periodically targets lymphocytes thought to be
integral to the pathological process of MS. Cladribine Tablets is
currently under clinical investigation and not approved for any use
in the United States, Canada and Europe.

About Multiple Sclerosis

Multiple sclerosis (MS) is a chronic, inflammatory condition of
the central nervous system and is the most common, non-traumatic,
disabling neurological disease in young adults. It is estimated that
approximately 2.3 million people have MS worldwide. While symptoms
can vary, the most common symptoms of MS include blurred vision,
numbness or tingling in the limbs and problems with strength and
coordination. The relapsing forms of MS are the most common.

All Merck Press Releases are distributed by e-mail at the same
time they become available on the Merck Website. Please go to
http://www.merckgroup.com/subscribe to register online, change your
selection or discontinue this service.

About Merck

Merck is a leading science and technology company in healthcare,
life science and performance materials. Around 50,000 employees work
to further develop technologies that improve and enhance life - from
biopharmaceutical therapies to treat cancer or multiple sclerosis,
cutting-edge systems for scientific research and production, to
liquid crystals for smartphones and LCD televisions. In 2015, Merck
generated sales of EUR 12.85 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and
chemical company. The founding family remains the majority owner of
the publicly listed corporate group. Merck, Darmstadt, Germany holds
the global rights to the Merck name and brand. The only exceptions
are the United States and Canada, where the company operates as EMD
Serono, MilliporeSigma and EMD Performance Materials.

ots Originaltext: Merck KGaA
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Gangolf Schrimpf
[phone]
Investor Relations
[phone]